15 terminated. 15 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 15 | Terminated 15 |
Follow Cystic Fibrosis: new trials by email Literature Review of Cystic Fibrosis trials Research Report on Cystic Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis Imipenem/Cilastatin/Relebactam - Cystic Fibrosis, Pneumonia, Bacterial | Phase 4 | Terminated | Hartford Hospital | 4 | 2023-01-03 | 2024-12-17 |
| Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations Symdeko, Ivacaftor and Symdeko - Cystic Fibrosis | Phase 4 | Terminated | University of Alabama at Birmingham | 1 | 2018-12-01 | 2025-04-16 |
| Functional Respiratory Imaging and Orkambi in CF Orkambi - Cystic Fibrosis | Phase 4 | Terminated | University Hospital, Antwerp | 12 | 2018-10-01 | 2020-04-08 |
| A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation LUM/IVA, activated smart device, de-activated smart device - Cystic Fibrosis | Phase 4 | Terminated | Vertex Pharmaceuticals Incorporated | 24 | 2016-06-01 | 2018-09-27 |
| Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa TIS or TIP - Chronic Lung Infection With Pseudomonas Aeruginosa in Cystic Fibrosis | Phase 4 | Terminated | Novartis Pharmaceuticals | 17 | 2015-01-27 | 2018-10-09 |
| Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles Tobramycin Inhalation Powder - Cystic Fibrosis | Phase 4 | Terminated | Novartis Pharmaceuticals | 32 | 2014-01-01 | 2017-03-29 |
| Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis Piperacillin-tazobactam combination product - Cystic Fibrosis | Phase 4 | Terminated | West Virginia University | 6 | 2012-09-01 | 2022-02-01 |
| The Effect of Inhaled N-Acetylcysteine Compared to Normal Saline on Sputum Rheology and Lung Function Acetylcysteine, normal saline - Cystic Fibrosis | Phase 4 | Terminated | University Hospital, Ghent | 19 | 2010-01-01 | 2011-08-15 |
| An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA) Omalizumab, Placebo, Itraconazole - Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis | Phase 4 | Terminated | Novartis Pharmaceuticals | 14 | 2008-11-01 | 2011-09-26 |
| Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control Pancrelipase - Exocrine Pancreatic Insufficiency, Chronic Pancreatitis | Phase 4 | Terminated | Digestive Care, Inc. | 3 | 2008-08-01 | 2013-02-22 |
| A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis Dornase alfa, Placebo - Cystic Fibrosis | Phase 4 | Terminated | Genentech, Inc. | 3 | 2008-06-01 | 2017-01-12 |
| A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC) Dornase alfa, placebo - Cystic Fibrosis | Phase 4 | Terminated | Genentech, Inc. | 27 | 2007-03-01 | 2017-05-16 |
| Prolonging the Duration of Peripheral Venous Catheters in Cystic Fibrosis People regular dilution of antibiotic in NS, higher dilution of antibiotic in NS - Cystic Fibrosis, Phlebitis | Phase 4 | Terminated | University of Florence | 60 | 2007-03-01 | 2015-10-29 |
| Effect of Non-Invasive Ventilation in Cystic Fibrosis Patient With Chronic Respiratory Failure. pressure support ventilator - Cystic Fibrosis, Chronic Respiratory Failure | Phase 4 | Terminated | Cochin Hospital | 36 | 2005-05-01 | 2013-02-13 |
| Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis ceftazidime - Cystic Fibrosis, Pseudomonas Aeruginosa | Phase 4 | Terminated | Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche | 120 | 2001-10-01 | 2006-06-05 |
Pseudomonas Infections (3) · Aspergillosis, Allergic Bronchopulmonary (1) · Exocrine Pancreatic Insufficiency (1) · Hypercapnia (1) · Lung Diseases (1) · Pancreatitis, Chronic (1) · Phlebitis (1) · Pneumonia, Bacterial (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (15) · Digestive System Diseases (15) · Genetic Diseases, Inborn (15) · Infant, Newborn, Diseases (15) · Pancreatic Diseases (15) · Respiratory Tract Diseases (15) · Lung Diseases (14) · Bacterial Infections and Mycoses (5) · Infections (5) · Bacterial Infections (4) · Gram-Negative Bacterial Infections (3) · Pathological Conditions, Signs and Symptoms (2) · Respiratory Tract Infections (2) · Aspergillosis (1) · Cardiovascular Diseases (1)
dornase alfa (2) · lumacaftor, ivacaftor drug combination (2) · Acetylcysteine (1) · Ceftazidime (1) · Itraconazole (1) · Lysine Acetyltransferase 5 (1) · Omalizumab (1) · Pancrelipase (1) · Piperacillin, Tazobactam Drug Combination (1) · Saline Solution (1) · imipenem, cilastatin and relebactam (1) · ivacaftor (1) · tezacaftor, ivacaftor drug combination (1)
Novartis Pharmaceuticals (3) · Genentech, Inc. (2) · Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche (1) · Cochin Hospital (1) · Digestive Care, Inc. (1) · Hartford Hospital (1) · University Hospital, Antwerp (1) · University Hospital, Ghent (1) · University of Alabama at Birmingham (1) · University of Florence (1) · Vertex Pharmaceuticals Incorporated (1) · West Virginia University (1)
United States (7) · Belgium (3) · France (2) · Germany (2) · Italy (2) · Canada (1) · Netherlands (1) · United Kingdom (1)
Michelle Freemer, M.D. (2) · Dominique Hubert, MD (1) · Filippo Festini, RN, BA, BSN (1) · Joseph L. Kuti, PharmD (1) · Kim Brouwer, PharmD, PhD (1) · Lisa Biondo, PharmD (1) · Lisa Gangarosa, M.D. (1) · Sabine Van Daele, MD, PhD (1) · Stijn Verhulst, MD, PhD (1)
PMID 12804435, PMID 26302738, PMID 32532226
2018 (1)